Infigratinib passed Phase I and II studies of advanced CCA with FGFR2 gene fusion or other FGFR genetic alterations that failed platinum-based chemotherapy (NCT02150967) [115]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.